Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06351683 · ClinicalTrials.gov registry record · Phase 2

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

A Phase 2 study of Lower Urinary Tract Symptoms and Overactive Bladder Syndrome, sponsored by Iman Al-Naggar, PhD.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT06351683 is a Phase 2 study of Lower Urinary Tract Symptoms and Overactive Bladder Syndrome that is actively recruiting participants, run by Iman Al-Naggar, PhD. The registered enrollment target is 50 participants, below the 748-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06351683, a Phase 2 study of Lower Urinary Tract Symptoms and Overactive Bladder Syndrome, is actively recruiting participants, sponsored by Iman Al-Naggar, PhD.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test the effect of a supplement called MitoQ (mitoquinol mesylate) on bladder symptoms such as urgency and frequency in women 50 years and older who have the metabolic syndrome. The main questions it aims to answer are: * Is the study design feasible and acceptable to participants? * Do participants taking the study drug get any improvement to their bladder symptoms compared to participants taking a placebo (a look-alike substance that contains no drug)? Participants will take 2 capsules of the study drug every morning for 4 months, answer many questions about their health including questions about their bladder health, perform physical and cognitive testing, give blood and urine samples, collect urine over 24 hour periods 3 times over the 4 months of the study, complete 3 day bladder diaries about how much they drink and void, undergo electrocardiograms, have their vitals and measurements (weight, height, waist circumference) taken, participate in 4 visits to the clinical research area and participate in many phone calls of varying length. Researchers will compare participants who were taking capsules containing MitoQ and participants taking capsules not containing MitoQ to see if MitoQ improves their bladder symptoms (urgency, frequency, nocturia, incontinence, etc.)

Interventions

  • OTHER Placebo
  • DRUG MitoQ (mitoquinol mesylate)

Study Locations (1)

Connecticut

  • UConn Health - Farmington

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-04-03
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Iman Al-Naggar, PhD

1 total trials

What the Registry Record Tells You About NCT06351683

The ClinicalTrials.gov registry entry for NCT06351683 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 748-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target (93% lower). The listed sponsor is Iman Al-Naggar, PhD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06351683 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06351683 about?

NCT06351683 is a clinical study titled "Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome". The goal of this clinical trial is to test the effect of a supplement called MitoQ (mitoquinol mesylate) on bladder symptoms such as urgency and frequency in women 50 years and older who have the metabolic syndrome. The main questions it aims to answer are: * Is the study design feasible and accept...

What is the current status of trial NCT06351683?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-04-03. Estimated completion is 2025-12-31.

What conditions does trial NCT06351683 study?

This clinical trial studies the following conditions: Lower Urinary Tract Symptoms, Overactive Bladder Syndrome.

What interventions are being tested in trial NCT06351683?

The interventions under investigation include: Placebo (OTHER), MitoQ (mitoquinol mesylate) (DRUG).

Who is sponsoring clinical trial NCT06351683?

This trial is sponsored by Iman Al-Naggar, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06351683 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lower Urinary Tract Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.